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The dropout rate was moderate. The pre-/posttreatment ef-
fects were high for the Hamilton Anxiety Rating Scale (stan-
dardized mean difference  1 1) and for the State-Trait Anxiety 
Inventory (standardized mean difference  1 0.87). The pro-
portion of patients reaching high end state functioning was 
48% (WE) and 56% (AR). WE and AR did not differ with regard 
to dropout rate or treatment effects. The treatment effects 
were stable at 6 month and 1 year follow-up.  Conclusion: 
This is the first study to show that a stand-alone exposure in 
sensu technique – WE – is efficacious in the treatment of 
GAD. Both AR and WE seem to represent effective principles 
of change in GAD.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Generalized anxiety disorder (GAD) is one of the most 
frequently occurring anxiety disorders with an estimated 
lifetime prevalence of 5–6%  [1] . A majority of patients 
with GAD have comorbid diagnoses, but even in pure 
cases patients with GAD are highly impaired  [2] . Many 
seek treatment in the primary-care system, where the dis-
order often remains unrecognized and untreated  [3] . 
GAD seldom remits without intervention  [4] and in-
creases the risk to develop comorbid disorders, particu-
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 Abstract 
 Background: Worry exposure (WE) is a core element of cog-
nitive-behavioral treatment for generalized anxiety disorder 
(GAD). Its efficacy as a stand-alone treatment method (with-
out further cognitive-behavioral therapy interventions) has 
never been tested.  We aimed to examine whether WE alone 
is as efficacious as the empirically supported stand-alone 
treatment for GAD, applied relaxation (AR).  Methods: In a 
randomized controlled study, 73 outpatients meeting DSM-
IV criteria for GAD as primary diagnosis were allocated to 
either WE or AR or a waiting list control group; in a 2nd ran-
domization procedure the waiting list subjects were re-
allocated to WE or AR. The treatment was manualized (15 
sessions with WE or AR), included 6-month and 1-year fol-
low-ups, as well as last observation carried forward and 
completer analyses, and was controlled for allegiance ef-
fects.  The Hamilton Anxiety Rating Scale and the State-Trait 
Anxiety Scale were used as primary outcome measures. Self-
report scales of anxiety, worrying and depression including 
negative metacognition about worrying and thought sup-
pression served as secondary outcome measures.  Results: 
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larly depression  [2] . The enhancement of the treatment 
effectiveness for GAD is therefore a mental health prior-
ity  [3] .
 The majority of psychotherapeutic treatment studies 
for GAD have compared cognitive-behavioral therapy 
(CBT) with a waiting list control group (WL)  [5, 6] . CBT 
was usually efficacious with a mean Hedges g of 0.82 for 
anxiety measures across all studies  [7] or a standardized 
mean difference (SMD) of –1.00 [95% confidence interval 
(CI) = –1.24 to –0.77]  [8] . Psychopharmacological treat-
ment was similarly successful  [7, 8] . Nevertheless, CBT 
seems to be less efficacious for GAD than for other anxi-
ety disorders and especially the benefits of the otherwise 
highly efficacious exposure techniques have been ques-
tioned in this disorder  [9] .
 The prominent avoidance theory of worry and GAD 
by Borkovec (e.g.  [10] ) suggests that the core symptom of 
GAD, uncontrollable worry, allows patients to cognitive-
ly avoid otherwise emotionally disturbing issues and per-
ceived dangers. From this point of view, worry is a pre-
dominantly cognitive-verbal activity that inhibits full 
emotional processing. As a result, disturbing emotional 
meanings of potentially dangerous and anxiously antici-
pated events cannot be fully tested or altered, making the 
repetitive processing of the feared stimuli probable  [11] .
 According to these assumptions, exposure treatment 
should also be successful in GAD. It can be applied by 
confronting physical stimuli (exposure in vivo) or imag-
ined stimuli (exposure in sensu). Given that worry is typ-
ically characterized by the focus on hypothetical future 
events, it follows that exposure in sensu should be a cru-
cial component of the treatment of GAD. Indeed, imagi-
nal exposure techniques targeting worry [‘worry expo-
sure’ (WE)] have been part of CBT treatment packages in 
trials for GAD (e.g.  [12, 13] ). These studies combined WE 
with various treatment elements such as muscle relax-
ation, breathing techniques, problem solving or cognitive 
restructuring, leaving the unique contribution of WE to 
the improvement unclear. The investigation into the 
unique effects of WE is, however, important. From a the-
oretical perspective, dismantling active CBT components 
for GAD aids in the understanding of the underlying 
functional mechanisms. From a practical point of view, it 
may offer a more parsimonious treatment approach.
 Based on these considerations, this study aimed to test 
the unique efficacy of WE alone, largely isolated from 
other therapeutic procedures. The treatment option best 
suited for comparison is applied relaxation (AR)  [14, 15] 
because, as WE, it concentrates on a single therapeutic 
target and has also demonstrated its efficacy in GAD  [8, 
15] . In AR, patients are taught to use relaxation skills in 
a highly effective and automatic manner whenever early 
signs of worrying, anxiety and/or tension are detected.
 The hypothesized psychological pathways of WE and 
AR clearly differ. While WE is based primarily on as-
sumptions of extinction and habituation  [16] , AR is 
grounded in the principles of skill mastery, in which re-
laxation is trained as a semiautomatic response to coun-
teract anxiety  [14, 15] . Neither treatment rationale explic-
itly posits the necessity of changing cognitive variables 
for treatment success. Cognitive variables (e.g. dysfunc-
tional thoughts) are, however, regarded as central to the 
maintenance of GAD  [17] . Therefore, we examined how 
WE and AR affect cognitive variables such as negative 
metacognitions about the dangerousness of worrying 
and thought suppression.
 In sum, the present trial aimed to test whether WE as 
a stand-alone exposure treatment for GAD is as effica-
cious as AR, the only empirically supported similarly 
parsimonious treatment approach to this condition. Spe-
cifically, we expected (a) WE to be at least as efficacious 
as AR and (b) both active treatments to be more effica-
cious than the WL. Furthermore, we tested the degree to 
which WE and AR differed in their ability to change cog-
nitive variables not specifically targeted during treatment 
(i.e. metacognition and thought suppression).
 Methods 
 Experimental Design and Patient Flow 
 The recruitment of patients occurred at the outpatient psycho-
therapy unit of the Technische Universität Dresden, Germany, 
from January 2003 to December 2004. The treatment and 12-
month follow-up of all participants was completed in September 
2006. The protocol was approved by the university ethics board 
and all participants gave written informed consent.
 Of the 688 potential participants who contacted the study 
group, 301 were screened positive for GAD via a telephone assess-
ment (see  fig. 1 for patient flow chart). The following in-person 
intake assessment was completed by 260 participants; 80 were el-
igible for inclusion in the study. Of these, 4 refused participation 
and 3 did not continue to meet inclusion criteria at the time of the 
randomization. A person independent of the study team random-
ized the remaining 73 participants using a random number gen-
erator to 1 of 3 conditions: (1) AR, (2) WE and (3) WL condition. 
According to the WL design, participants who completed the WL 
condition were subsequently rerandomized to 1 of the 2 active 
treatment conditions. Since the randomization was not balanced, 
it resulted in nonequal groups.
 The inclusion criteria were a primary DSM-IV diagnosis of 
GAD as established using a standardized instrument (Munich 
Composite International Diagnostic Interview  [18] ) and age be-
tween 18 and 70 years. The exclusion criteria were serious physical 
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impairment (DSM-IV axis III), any lifetime history of schizo-
phrenia, bipolar disorder, seizure or organic brain syndrome, 
substance abuse or dependence within the past year, serious per-
sonality disorder, any concurrent psychotherapeutic intervention 
or benzodiazepine use. One patient presented with benzodiaze-
pine use and was randomized after successful tapering off of this 
medication. Use of antidepressant drugs was not an exclusion cri-
terion when begun before and maintained on a stable dosage 
throughout the study (n = 3 in WE, n = 5 in AR).
 Participants 
 Of the 73 randomized participants, 31 were assigned to the 
WL. Following completion of the WL, 14 of the WL were ran-
domly allocated to AR and 12 to WE. One participant of the WL 
dropped out during the waiting period. Four others completed 
the WL but were excluded from further participation because 
they no longer met the inclusion criteria for the study (1 developed 
a somatic disorder, 1 was suicidal, and 2 did no longer meet the 
diagnostic criteria for GAD). Overall, 36 participants were ran-
domly assigned to the WE and 32 to AR.
 The majority of the participants were female (n = 52; 71%). The 
mean age was 45.4 years [standard deviation (SD) = 12.48]. The 
sample had an average level of education: most of the participants 
reported completing a 10th-grade education (n = 35, 48%), ap-
proximately a third at least a 12th-grade education (n = 27; 37%) 
and less than a fifth an 8th-grade education (n = 11; 15%). Most 
participants were married (n = 52, 71%), while 13 (17%) were un-
married, 7 (10%) indicated that they were divorced or lived apart 
from their spouse, and 1 person (1%) was widowed.
 Treatment 
 Both treatments were applied using a manualized protocol 
covering 15 sessions. Treatments were scheduled weekly with 
homework assignments at the end of each session. When consen-
Telephone GAD screening (n = 688) 
Completed 12-month post-
treatment follow-up (n = 27) 
Dropout
n = 4 Refused participation 
n = 3   Failed to meet    
inclusion criteria    
before randomization 
Completed 6-month post-
treatment follow-up (n = 24) 
Dropouts
(n = 4 1st randomization; 
n = 3 2nd randomization) 
Completed treatment (n = 29) 
Positive GAD screening (n = 301) 
Standardized diagnostic interview face to face 
Eligible (n = 80) 
1st
randomization 
Worry exposure (n = 12) 2nd
randomization 
for WL patients 
Waiting list (n = 31)Worry exposure (n = 24) Applied relaxation (n = 18) 
Randomization (n = 73) 
Completed 12-month post-
treatment follow-up (n = 26) 
Completed 6-month post-
treatment follow-up (n = 27) 
Completed treatment (n = 28) 
Dropouts
(n = 2 1st randomization; 
n = 2 2nd randomization) 
Applied relaxation (n = 14)
Applied relaxation total (n = 32) Worry exposure total (n = 36) Final number of 
patients enrolled 
per group 
15 weeks 
n = 1 Dropout 
n = 4 Excluded from 
rerandomization 
 Fig. 1. Patient flow chart. 
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sually agreed upon by the therapist and supervisor, 2 additional 
treatment sessions were allowed in both treatment conditions.
 Applied Relaxation 
 The AR manual based on Öst’s treatment protocol  [14] com-
menced with psychoeducation in which the disorder was ex-
plained based on an ideographically applied vicious circle model 
that stressed the role of bodily arousal in the maintenance of the 
presented problem. No references were made to the possible role 
of automatic thoughts or beliefs. The patients were told that they 
could learn relaxation procedures to reduce their autonomic 
arousal and that this would help them cope with situations in 
which they had previously experienced excessive tension or wor-
rying. Beginning with progressive muscle relaxation, the patients 
were trained in different steps of relaxation procedures during the 
subsequent 6–7 sessions. They were also taught to identify early 
signs of tension and anxiety. In the final stage of therapy, applica-
tion of rapid relaxation following the recognition of the first signs 
of anxiety, as provoked by imagining feared situations, was prac-
ticed in the session. The patients then applied their relaxation 
skills whenever signals of tension, worrying or anxiety occurred 
in daily life. There was no explicit confrontation instruction, al-
though transfer to everyday situations was encouraged at the end 
of treatment (sessions 14 and 15). The treatment was completed 
with relapse prevention.
 Worry Exposure 
 WE followed the protocol by Becker and Margraf  [19] . Similar 
to the AR, the WE treatment began with psychoeducation but ex-
plained the disorder using concepts of avoidance. Once again, no 
specific references were made to the role of automatic thoughts or 
beliefs. Using the concept of habituation, the patients were in-
formed that symptom reduction could be achieved by directly ex-
posing themselves to their worry. The treatment commenced 
with self-monitoring of worry. WE began in the 3rd session and 
continued through the 10th. Concurrently, avoidance and reas-
surance behaviors were addressed and systematically reduced. 
The final stage of therapy targeted generalization and relapse pre-
vention.
 In both treatment conditions, the patients were assigned 
homework exercises. In WE the homework consisted in practic-
ing WE alone; in AR it focused on learning relaxation skills and 
then gradually applying them whenever first signs of arousal were 
noticed. Diaries on the completion of homework assignments 
were kept throughout the study.
 Therapists, Supervision and Treatment Integrity 
 The study therapists were clinical psychologists in postgradu-
ate psychotherapy training. All therapists participated in 2 days 
of extensive training for each of the manualized interventions. All 
therapy sessions were videotaped and adherence monitored dur-
ing weekly team supervisions by the primary investigator. After 
study completion, the session videos were randomly selected for 
evaluation by 2 independent raters. The sessions were rated for 
treatment adherence and therapeutic competence. For the pur-
pose of independent rating, the treatment course was divided into 
4 phases (i.e. psychoeducation/rationale, learning confrontation 
or relaxation techniques, application of confrontation or relax-
ation techniques and relapse prevention) and 25% of the sessions 
in each of these phases were examined. Treatment adherence and 
competence ratings were based on a 4-point scale (0–3, with the 
anchor points ‘bad’ to ‘very good’).
 Assessments 
 Independent Assessor Ratings 
 DSM-IV diagnoses were evaluated using the DSM-IV Munich 
Composite International Diagnostic Interview  [18] , a modified 
version of the WHO Composite International Diagnostic Inter-
view  [20] . The Hamilton Anxiety Rating Scale (HAMA)  [21] , in-
cluding subscales of somatic and psychic symptoms) and the 
Hamilton Depression Scale (HAMD)  [22] were also adminis-
tered, measuring the overall severity of anxiety and depressive 
symptomatology during the prior week. The HAMA was used as 
a primary outcome measure.
 Self-Report Measures 
 Self-reported global anxiety symptoms were measured using 
the trait version of the State-Trait Anxiety Inventory (STAI), Ger-
man version  [23] . The STAI served as the second primary out-
come measure. The Penn State Worry Questionnaire (PSWQ) 
 [24, 25] was used to assess trait worry and to capture the general, 
excessive and uncontrollable characteristics of pathological wor-
ry. Beliefs about the subjective danger and uncontrollability of 
worry were measured with the Metacognition Questionnaire 
(MCQ)  [26, 27] . The White Bear Suppression Inventory (WBSI) 
 [28, 29] evaluated the tendency to chronically suppress one’s own 
thinking. The Beck Depression Inventory (BDI) [German ver-
sion:  30 ] assessed the severity of depressive symptoms. The Glob-
al Severity Index (GSI) of the Brief Symptom Inventory (BSI)  [31] 
was used to assess general psychopathology. Finally, therapeutic 
alliance was measured with the Helping Alliance Questionnaire 
 [32, 33] and treatment expectations with a single item after the 1st 
session.
 Therapist Ratings 
 Following treatment, the therapists rated their patients’ global 
improvement across all symptomatology using the Clinical Glob-
al Impression of Improvement (CGI)  [34] .
 Data Analysis 
 Pretreatment Analysis 
 Prior to posttest evaluations, the data were screened for sys-
tematic group differences in sociodemographic variables (i.e. age, 
sex, education level, marital status and work status) and clinical 
characteristics (i.e. number of comorbid diagnoses, treatment ex-
pectations). The groups differed only with respect to the number 
of comorbid diagnoses, which were significantly more frequent in 
AR (M = 1.89, SD = 0.92) than in WL (M = 1.37, SD = 0.67) [mean 
difference (MD) = 0.53, 95% CI = 0.1–0.9, p  ! 0.012]. No signifi-
cant discrepancies concerning comorbid diagnoses were found 
between the 2 treatment groups (WE: M = 1.59, SD = 0.82). All 
analyses were run with and without controlling for the number of 
comorbid diagnoses. No differences occurred between these sets 
of analyses. Therefore, only the uncontrolled evaluations will be 
reported.
 Completer Analyses 
 To assess the treatment effects on the outcome criteria, the 
postassesment scores were regressed on 2 dummy variables rep-
resenting either of the active treatment conditions as compared to 
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the WL condition. Such linear regressions are equivalent to ANO-
VA models with the benefit that they calculate CI of regression 
coefficients, which are robust against clustering of observations 
within patients when using the Huber-White sandwich estimator 
 [35] . Furthermore, the resulting CI are also robust against often 
unmet assumptions of ANOVA models (e.g. variance homogene-
ity  [35] ). Post hoc comparisons were made between the 2 active 
treatments. In additional analyses, we adjusted the respective 
baseline score in an attempt to reduce individual variances in out-
comes with the intent to increase statistical power. All analyses 
were replicated using parametric bootstrap CIs from linear re-
gressions while repeating the study design when drawing boot-
strap samples (i.e. sampling all observations per person and sam-
pling stratified by treatment condition  [36] ). This approach 
guards against misleading results when using large-sample statis-
tics in relatively small samples. These analyses did not result in 
differences in any measure and will therefore not be reported. 
Stata 9.2  [37] was used for these investigations. The results for all 
analyses are reported as regression coefficients, that is, MD as 
compared to the WL control or one of the active conditions de-
pending on the specific analysis. Standardized mean differences 
(SMD) were computed by dividing the outcomes by the SD in the 
entire sample before treatment.
 LOCF Analyses 
 In addition to the completer analyses, calculations were re-
peated after replacing missing values for the dropout cases with 
their last observation carried forward values (LOCF).
 End-State Functioning and Treatment Response 
 End-state functioning was assessed using the HAMA. This 
measure served to estimate the degree to which the participants 
returned to normative functioning. Consistent with previous 
consensus conferences  [38] , a HAMA score of 10 or less was used 
to delineate normative functioning. HAMA cut scores of 7, 8 and 
9 were also reported.
 The treatment response was measured via 2 modes of assess-
ment: the therapists’ clinical judgment and pre-/posttreatment 
differences in patient self-reports. Consistent with Dahl et al.  [39] , 
a 50% reduction in HAMA total scores was used to define thera-
pist rated treatment responses. The therapists also measured 
treatment responses with the CGI. The patients who were judged 
to have ‘very much improved’ or ‘much improved’ were consid-
ered treatment responders, whereas nonresponders were those 
with ‘minimal improvement’, no change or worsening.
 Results 
 Attrition 
 Of the 73 randomized participants, 57 (78%) complet-
ed the treatment. Twenty-nine participants finished the 
WE treatment. The reasons for the 7 dropouts (19%) were: 
problems to integrate the treatment appointments into 
the job schedule (n = 2), rejection of the treatment con-
cept (n = 1), personal reasons (n = 1) and the feeling of the 
therapy being too exhausting (n = 1). For 2 patients no 
dropout reason was available. Twenty-eight participants 
completed the AR treatment. The reasons for the 4 drop-
outs (13%) were: external circumstances (n = 1), the feel-
ing of the therapy being too exhausting (n = 1), and in 2 
cases a perceived lack of fit between the treatment expec-
tations and the actual treatment. The number of drop-
outs did not differ between the 2 active treatment groups, 
  2 (1) = 0.60, p  1 0.05.
 Treatment Adherence 
 Overall, the therapists’ treatment adherence was good 
to very good (M = 2.31; SD = 0.55). Similarly, the inde-
pendent assessors rated the general therapeutic compe-
tencies as good to very good in both conditions (M = 2.77, 
SD = 0.26). No differences in treatment adherence and 
competence were found between the treatment groups.
 Posttreatment Analyses 
 Completer Analyses 
 To test the treatment effects, a series of multiple re-
gression analyses were conducted using data from the 29 
AR and the 28 WE treatment completers and the 29 wait-
ing list completers. All primary and secondary measures 
decreased significantly from before to after treatment in 
the AR and WE groups (see  tables 1 and  2 ). In contrast, 
there was no significant decrease in the WL group. Given 
significant changes over time, posttreatment scores were 
compared across conditions controlling for pretreatment 
scores. The AR and WE groups had significantly lower 
scores than the WL group on all measures except for the 
BDI in the WE condition. Once again, no significant dif-
ferences emerged between the AR and WE groups.
 LOCF Analyses 
 Accounting for participant dropouts during treat-
ment, the posttreatment analyses were repeated for all 
comparisons. They did not result in any significant dif-
ferences compared to the completer analyses and will 
therefore not be reported any further (data are available 
upon request). For completer and LOCF analyses, we also 
tested for differences between the first randomized con-
trolled trial and the 2nd crossover randomized controlled 
trial and found nearly identical results for both (results 
available on request).
 Treatment Response and End-State Functioning 
 After treatment, about half of the completers [n = 15 
(48%) of the WE group and n = 15 (56%) of the AR group] 
reached full end-state functioning as indicated by a 
HAMA score of 10 or less. For comparison, n = 15 (48%), 
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n = 12 (41%) and n = 9 (31%) in the WE group and n = 13 
(48%), n = 11 (41%) and n = 6 (22%) in the AR group 
reached a HAMA score of at most 9, 8 or 7, respectively.
 Regarding treatment response, n = 13 (45%) in the WE 
group and n = 14 (47%) in the AR group reached a 50% 
reduction in HAMA scores after treatment. The response 
rates were higher when based on the therapists’ CGI rat-
ings, with n = 16 (55%) of the WE group and n = 17 (61%) 
of the AR group responding.
 Follow-Up Analyses 
 Completer Analyses 
 To examine the stability of change and possible im-
provement following treatment, the 2 active treatment 
conditions were tested 6 and 12 months after treatment. 
Six months following treatment, significant further im-
provements were observed in the WE condition only (see 
 tables 3 and  4 ). Specifically, the WE improved signifi-
cantly relative to after treatment on measures of worry 
frequency (PSWQ) and salient cognitive variables (WBSI; 
as a statistical trend: MCQ II). At the 12-month follow-
up, improvements noted in the WE condition were main-
tained at a significant level when compared to after treat-
ment. In addition, the AR group improved significantly 
in 1 of the 2 salient cognitive variables (i.e. MCQ II). Be-
tween-group comparisons of the AR and WE conditions 
did not result in any significant differences in any mea-
sures at either the 6- or 12-month follow-up. Taken as a 
whole, these results suggest that the treatment effects im-
proved or were maintained in the year following treat-
ment for both groups.
 LOCF Analyses 
 Accounting for the dropouts during the study period, 
follow-up analyses were repeated for all comparisons. In 
contrast to the completer analyses, they led to slightly dif-
ferent results. Specifically, the statistical trend toward im-
provement in the WE condition on the MCQ II (see  ta-
ble 4 ) was not maintained at 6 but at 12 months of follow-
up. All other within- and between-group comparisons 
remained unchanged (results available on request).
 Discussion 
 This is the first randomized controlled study examin-
ing the efficacy of WE as stand-alone treatment for pa-
tients with DSM-IV GAD, using a WL group and an em-
pirically tested parsimonious treatment – AR – as com-
parisons. The patients exhibited distinct improvements 
on all primary and secondary outcome measures in both 
active treatment conditions. Accordingly, symptoms of 
anxiety and depression, including excessive worrying, 
negative metacognitive appraisal of worrying and thought 
suppression were reduced. These improvements appeared 
stabile, as indicated by 6- and 12-month follow-up assess-
ments. No differences were found between the 2 active 
treatment groups in any measure.
 With regard to AR, the results replicate the previously 
demonstrated efficacy  [8, 15] for GAD. With respect to 
WE, no other controlled trial has directly and exclusively 
tested the therapeutic effects of this method. The fact that 
WE proved to be effective even as a stand-alone treatment 
raises new questions. For example it should be examined 
Table 1. Means 8 SD for selected outcome measures before and after treatment for completers
Waiting list control group Applied relaxation Worry exposure
n before after n before after n before after
HAMA 29 23.3387.02 21.1587.16 28 22.7187.35 12.2188.82 29 21.687.23 12.1987.82
HAMA somatic 29 10.5984.78 9.0284.33 28 9.8683.96 5.6484.24 29 8.9784.72 5.184.47
HAMA psychic 29 12.7783.37 12.283.68 28 12.8384.38 6.6785.00 29 12.783.99 7.0883.99
STAI-T 23 52.9187.42 52.6586.88 26 51.6985.08 45.0488.71 26 51.687.93 45.2389.55
PSWQ 29 57.0087.78 57.0389.85 28 56.8488.15 49.5589.49 27 61.1810.40 54.33810.13
MCQ II 29 41.9988.57 41.6888.96 28 43.4687.98 36.4989.27 29 46.4810.30 39.0589.00
WBSI 29 50.3589.13 48.5889.04 28 47.789.86 39.36811.47 27 55.2811.00 46.22812.20
BSI-GSI 30 0.6880.35 0.7780.37 28 0.8180.44 0.5180.46 27 1.0080.60 0.6680.48
HAMD 29 14.5584.82 12.9784.86 27 13.3385.31 6.6385.76 29 12.484.96 6.0784.44
BDI 28 13.4984.65 12.6685.34 26 15.2287.07 9.3888.11 27 13.687.46 10.2587.11
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Table 2. Pre-/posttreatment effect and comparisons of posttest measures between groups (regression analyses) for selected outcomes 
for both active treatment groups and WL group (completers)
Participants Within-group comparison 
(before vs. after)
Comparison of posttest measures 
between groups
SMD unstandardized SMD unstandardized
MD p MD p
HAMA WL 29 –0.31 –2.18 (–5.0 to 0.7) 0.13 ref. ref.
AR1 28 –1.50 –10.50 (–14.0 to –7.0) <0.01 –1.23 –8.61 (–12.5 to –4.6) <0.01
WE1 29 –1.35 –9.43 (–11.9 to –7.0) <0.01 –1.15 –8.03 (–11.6 to –4.5) <0.01
HAMA somatic WL 29 –0.36 –1.56 (–3.2 to 0.0) 0.06 ref. ref.
AR1 28 –0.98 –4.23 (–6.1 to –2.4) <0.01 –0.70 –3.01 (–4.9 to –1.0) <0.01
WE1 29 –0.89 –3.86 (–5.3 to –2.4) <0.01 –0.71 –3.08 (–5.2 to –0.9) <0.01
HAMA psychic WL 29 –0.15 –0.57 (–2.3 to 1.1) 0.50 ref. ref.
AR1 28 –1.60 –6.16 (–8.1 to –4.2) <0.01 –1.44 –5.55 (–7.7 to –3.3) <0.01
WE1 29 –1.45 –5.59 (–7.2 to –3.9) <0.01 –1.32 –5.08 (–7.0 to –3.1) <0.01
STAI-T WL 23 –0.04 –0.26 (–2.4 to 1.9) 0.80 ref. ref.
AR1 26 –0.91 –6.65 (–9.7 to –3.6) <0.01 –0.92 –6.72 (–10.6 to –2.8) <0.01
WE1 26 –0.87 –6.38 (–9.7 to –3.0) <0.01 –0.88 –6.50 (–10.0 to –2.9) <0.01
PSWQ WL 29 0.03 0.27 (–2.3 to 2.9) 0.83 ref. ref.
AR1 28 –0.79 –7.29 (–10.5 to –4.0) <0.01 –0.82 –7.54 (–11.6 to –3.4) <0.01
WE1 27 –0.73 –6.76 (–9.6 to –3.9) <0.01 –0.65 –5.98 (–10.0 to –1.9) <0.01
MCQ II WL 29 –0.03 –0.30 (–3.2 to 2.6) 0.83 ref. ref.
AR1 28 –0.78 –6.97 (–9.8 to –4.1) <0.01 –0.70 –6.21 (–10.1 to –2.2) <0.01
WE1 27 –0.83 –7.38 (–10.1 to –4.6) <0.01 –0.64 –5.69 (–9.2 to –2.1) <0.01
WBSI WL 29 –0.18 –1.77 (–4.9 to 1.4) 0.26 ref. ref.
AR1 27 –0.84 –8.34 (–12.1 to –4.5) <0.01 –0.75 –7.45 (–12.1 to –2.7) <0.01
WE1 27 –0.9 –8.93 (–12.9 to –4.9) <0.01 –0.56 –5.57 (–10.2 to –0.9) <0.05
BSI-GSI WL 30 0.19 0.09 (0.0 to 0.2) 0.19 ref. ref.
AR1 28 –0.63 –0.29 (–0.4 to –0.1) <0.01 –0.70 –0.33 (–0.5 to –0.1) <0.01
WE1 27 –0.73 –0.34 (–0.5 to –0.1) <0.01 –0.63 –0.30 (–0.5 to –0.1) <0.01
HAMD WL 29 –0.31 –1.59 (–3.5 to 0.4) 0.11 ref. ref.
AR1 27 –1.32 –6.70 (–8.9 to –4.5) <0.01 –1.13 –5.74 (–8.3 to –3.1) <0.01
WE1 29 –1.24 –6.28 (–8.0 to –4.6) <0.01 –1.15 –5.82 (–8.2 to –3.4) <0.01
BDI WL 28 –0.12 –0.83 (–2.8 to 1.1) 0.39 ref. ref.
AR1 26 –0.88 –5.84 (–8.4 to –3.3) <0.01 –0.67 –4.48 (–7.3 to –1.6) <0.01
WE1 27 –0.51 –3.40 (–5.6 to –1.2) <0.01 –0.38 –2.52 (–5.4 to 0.4) 0.09
WE vs. AR2 HAMA 0.08 0.57 (–3.3 to 4.5) 0.77
HAMA somatic –0.02 –0.07 (–2.1 to 2.0) 0.95
HAMA psychic 0.12 0.47 (–1.7 to 2.7) 0.67
STAI-T 0.03 0.25 (–4.1 to 4.6) 0.91
PSWQ 0.17 1.56 (–2.5 to 5.6) 0.44
MCQ II 0.06 0.52 (–3.0 to 4.1) 0.77
WBSI 0.19 1.87 (–3.4 to 7.2) 0.48
BSI-GSI 0.08 0.04 (0.1 to 0.2) 0.72
HAMD –0.02 –0.08 (–2.5 to 2.3) 0.94
BDI 0.29 1.95 (–1.1 to 5.0) 0.20
Figures in parentheses are 95% CI. Ref. = reference group.
1 For between-group comparisons WL is used as reference group. 2 With control for prelevels.
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in which cases the use of WE alone has advantages over 
(or is at least equally effective as) the use of a heteroge-
neous set of interventions, whether this method has the 
potential to reduce the treatment duration and with 
which other interventions it combines optimally. These 
questions are particularly relevant in light of our finding 
that for both single-method treatments the response and 
remission rates were only moderate and did not exceed 
the typical rates found in other studies  [8, 9] . In fact, some 
authors suggest to complement CBT interventions for 
GAD with additional methods such as interpersonal-
experiential strategies  [40] . Nevertheless, the improve-
ments noted in our study of single-method treatments 
may represent a valuable therapeutic and research ave-
Table 3. Means 8 SD for selected outcome measures at follow-up (6 and 12 months) for completers
Applied relaxation Worry exposure
 n FU 6 n FU 12 n FU 6 n FU 12
PSWQ 27 49.2288.10 26 48.3888.56 23 50.21812.21 26 51.09812.62
MCQ II 27 35.7887.52 27 34.2288.67 23 36.00811.36 26 35.38810.38
WBSI 27 39.52811.52 27 38.27811.64 23 40.91814.25 26 41.27815.3
BSI-GSI 26 0.5180.44 27 0.5180.44 23 0.6880.68 26 0.6380.69
BDI 26 8.4385.65 25 10.0786.89 22 8.6487.12 26 9.4289.83
Table 4. Posttreatment to follow-up effect (regression analyses) and comparison of follow-up measurements of active treatment groups 
for completer outcomes
6-month posttreatment follow-up 12-month posttreatment follow-up
n SMD MD p n SMD MD p
PSWQ1
AR 27 –0.01 –0.13 (–2.4 to 2.2) 0.91 26 –0.14 –1.25 (–4.0 to 1.5) 0.36
WE 23 –0.38 –3.48 (–6.6 to –0.3) <0.05 26 –0.34 –3.14 (–6.2 to 0.1) <0.05
MCQ II1
AR 27 –0.01 –0.10 (–2.1 to 1.9) 0.92 27 –0.32 –2.80 (–5.2 to –0.4) <0.05
WE 23 –0.35 –3.14 (–6.3 to 0.1) 0.05 26 –0.41 –3.66 (–6.3 to –1.0) <0.01
WBSI1
AR 27 0.03 0.30 (–2.3 to 2.9) 0.81 27 –0.13 –1.31 (–4.8 to 2.2) 0.45
WE 23 –0.59 –5.91 (–10.1 to –1.7) <0.01 26 –0.50 –4.96 (–9.4 to –0.5) <0.05
BSI-GSI1
AR 26 –0.01 –0.01 (–0.1 to 0.1) 0.90 27 –0.04 –0.02 (–0.1 to 0.1) 0.73
WE 23 0.08 0.04 (–0.1 to 0.2) 0.62 26 –0.04 –0.02 (–0.2 to 0.1) 0.80
BDI1
A 26 –0.21 –1.37 (–4.1 to 1.3) 0.30 25 0.00 0.03 (–2.4 to 2.4) 0.98
WE 22 –0.05 –0.32 (–3.2 to 2.6) 0.82 26 –0.11 –0.73 (–3.8 to 2.3) 0.63
WE vs. AR follow-up measurement2
PSWQ –0.13 –1.22 (–5.8 to 3.4) 0.60 –0.04 –0.33 (–5.3 to 4.6) 0.89
MCQ II –0.10 –8.44 (–5.3 to 3.7) 0.71 –0.10 –0.87 (–5.2 to 3.4) 0.69
WBSI –0.34 –3.30 (–9.4 to 2.7) 0.27 –0.27 –2.73 (–8.9 to 3.4) 0.38
BSI-GSI 0.25 0.12 (–0.1 to 0.4) 0.34 0.01 0.00 (–0.2 to 0.2) 0.97
BDI 0.32 2.15 (–1.8 to 6.1) 0.29  0.11 0.71 (–3.7 to 5.1) 0.75
Figures in parentheses are 95% CI.
1 Follow-up vs. posttreatment effect. 2 With control for prelevels.
 Hoyer /Beesdo /Gloster /Runge /Höfler /
Becker 
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nue. There is presently no discussion on how to optimize 
exposure in sensu in GAD or how to optimize the AR 
protocol for this specific group of patients. Hopefully, our 
results may help stimulate such debates. Furthermore, 
studies inquiring into the nature of the psychological and 
neurobiological processes underlying the anxiety-reduc-
ing effects of exposure in sensu (of which WE is just 1 
example) seem of interest.
 One particularly interesting finding was that all sec-
ondary outcome measures designed to assess cognitive 
and metacognitive change  [41] were effectively reduced 
despite the fact that no explicit cognitive intervention 
was applied. These results are consistent with other 
studies that question the necessity of explicit cognitive 
interventions [ 42 and references therein,  43 ]. Although 
the assumed pathways through which WE and AR 
brought about change clearly differ, they may have a 
higher-level construct in common. For instance, both 
treatments enable the patient to feel more competent 
when confronted with up-coming worries. This form of 
competency is often described as self-efficacy and may 
indirectly influence related (negative) beliefs about wor-
rying as well as about the necessity to control one’s own 
thinking.
 Our analyses did not reveal any moderating influence 
of psychiatric comorbidity on the treatment outcome, as 
the improvements were maintained even after control-
ling for additional comorbid disorders. However, this 
does not mean that comorbid disorders are generally neu-
tral for the therapeutic effect. Moderate and severe forms 
of depression are seen as a contraindication for WE and 
AR and patients reaching the respective degree of sever-
ity of depression were excluded from the present study. 
Consequently, our results only confirm the view that WE 
and AR can be applied successfully when mild depression 
or other comorbid conditions such as anxiety disorders 
are present. Furthermore, other potential moderating 
variables such as treatment expectations or the quality of 
the therapeutic alliance where not found to influence the 
results in a significant way.
 Although this study utilized several measures to re-
duce and control bias, it had a number of limitations. 
First, expert ratings for anxiety symptoms (HAMA) were 
not conducted at follow-up. Similarly, blinded reviewers 
did not reassess comorbid diagnoses following treatment. 
However, all self-report data in this trial clearly support 
the view that the symptom reduction achieved through 
treatment was stable at both follow-up measurements. Fi-
nally, the study did not include any psychological placebo 
condition aside from the WL. The use of such a condition 
might have reduced the effect sizes observed with respect 
to the WL.
 The reported effect sizes do not allow direct compari-
sons with other controlled trials in GAD. The character-
istics of our sample include the fact that the HAMA pre-
scores were only moderate, since elevated HAMA scores 
were not a criterion for inclusion. Consequently, the range 
for HAMA reduction was lower than in other studies. 
The specifics of our therapists include that they were rel-
atively young and inexperienced. This may increase their 
adherence to the treatment manual. It is also possible, 
however, that the treatment effects would have been larg-
er with more experienced therapists. Given that this study 
was designed to test explicit hypotheses of therapeutic 
principles, we felt that the benefits of guarding against 
therapy allegiance effects outweighed the disadvan-
tages.
 In summary, in this first randomized control trial of 
WE as a stand-alone treatment for GAD we found this 
method to be as efficacious as AR. Although both WE 
and AR seem to represent effective principles of change 
in GAD, these treatments should be further developed 
and/or more systematically combined with other treat-
ment components.
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